Fig. 2From: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort studyHCC-free survival for patients with HBV (a) and HCV (b) grouped according to the use of ACEIs and ARBs within 6Â months after the index dateBack to article page